BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: GlobeNewswire
- Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturity PALO ALTO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today that it intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of notes. The Company intends to use a portion of the net proceeds from the offering to repay all outstan
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.MarketBeat
- BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.MarketBeat
- What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]Yahoo! Finance
- BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.MarketBeat
- BridgeBio to Participate in December Investor ConferencesGlobeNewswire
BBIO
Earnings
- 10/29/25 - Miss
BBIO
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- BBIO's page on the SEC website